Praxis Precision Medicines (PRAX) management remains confident in regulatory approval and the commercial prospects for ulixacaltamide, its investigational treatment for essential tremor, RBC Capital Markets said Thursday in a report.
At a presentation, the company said it is continuing preparations for a potential launch while expanding physician awareness of the treatment, according to RBC. Management also presented additional data that further reinforced ulixacaltamide's clinical profile, the report said.
Management additionally outlined a goal of building a leading neuroscience company capable of generating more than $20 billion in revenue, supported by its current portfolio and future pipeline opportunities, RBC said.
"Still, we remain focused on the near-term catalysts, and believe there is a path to significant upside, and continue to like the setup at these levels," the report said.
RBC has an outperform rating with speculative risk on Praxis shares and a $478 price target.
Price: 316.83, Change: -7.94, Percent Change: -2.44
Comments